Be the most trusted biotech company


Henlius Wins “Most Innovative Global Biopharmaceutical Company 2021”Hosted by GHP Magazine

2021-05-14
Recently, global information sharing platform Global Health & Pharma Magazine from UK (hereinafter referred to "GHP") has announced the winners of the 2021 Biotechnology Awards. By virtue of the differentiated and comprehensive innovation capabilities, Henlius wins the award of “Most Innovative Global Biopharmaceutical Company 2021”. The Biotechnology Awards cast a shining light on the pioneers within this evolving and crucial sector. Final judgement is made based on various criteria such as: business growth (either sustained or rapid), significant innovations, etc. The recognition not only highlights Henlius’ innovation capabilities, but also recognizes the company’s influence in the global biopharmaceutical markets.

Innovation is the power fueling the development of the biopharmaceutical companies.  Henlius continues its momentum for a diversified innovation by enhancing internal innovation capacityies and reaching out to more strategic partners. Building upon the accumulated resources and technologies in the field of biologic medicines, Henlius has been establishing a forward-looking presence in innovative targets, bispecific antibodies as well as the antibody-drug conjugates (ADC). With anti-PD-1 product as core, Henlius has replenished a diversified and differentiated innovation pipeline covering the candidate targets including HER2, EGFR, PD-1/L1, c-MET, S1 Protein of SARS-CoV-2, LAG-3, TROP2, BRAF,etc. with the aim of addressing some of the most significant unmet needs.
 
Serplulimab injection (anti-PD-1 mAb) is the core innovative product independently researched and developed by Henlius. Combined with other products, it could be applied in the treatment of solid tumors for immuno-oncology therapy. In April 2021, its New Drug Application (NDA) for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy has been accepted by the National Medical Products Administration (NMPA) and granted priority review status. Serplulimab is potentially to be the first anti-PD-1 mAb indicated for MSI-H solid tumors in China. For this indication, patients are screened by specific MSI-H tumor markers, rather than by different tumor types, with a wide range of patient population. Henlius adopts the “Combo+Global” development strategy for serplulimab injection, focusing on indication differentiation and combination therapy, with a total of 10 clinical trials conducted worldwide.
 

With the implementation of “Combo+Global” strategy, Henlius will continue to explore pipeline opportunities and gather pace in diversified innovation, underscoring its commitments to bringing high-quality and affordable biological therapies to patients worldwide.


About GHP


GHP is a global information sharing platform and a multi-disciplinary member’s community. The publication was established to enhance communication networks and collaboration across all themes and disciplines within three main categories: Human, Animal & Environmental Health. GHP has a circulation of 260,000 and is one of the digital magazines published by AI Global Media, a UK based publisher which has published over 200 worldwide publications to its name since 2010. 
https://www.ghp-news.com/